Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma (NASDAQ: STRO) reported full-year 2025 results and program updates. Key financials: $141.4M cash at December 31, 2025 and $102.5M 2025 revenue (vs. $62.0M in 2024). A $110.0M equity offering extends runway into at least Q2 2028.
Clinical highlights: three cohorts dosed in the Phase 1 STRO-004 program with initial data expected mid-2026; STRO-227 IND targeted for 2026; an Astellas-partnered iADC has entered the clinic, triggering near-term milestones.
Sutro Biopharma (NASDAQ: STRO) announced management participation in multiple investor conferences in early March 2026, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.
Webcasts of fireside chats at TD Cowen and Citizens will be accessible via the company’s Events & Presentations page, with archived replays available for at least 30 days.
Sutro Biopharma (NASDAQ: STRO) will participate at the 16th World ADC London Summit in London, UK, February 23-26, 2026. Senior scientist Hans-Peter Gerber, Ph.D. will join panel discussions and present on dual-payload ADC efficacy and safety.
According to the company, plenary content will be posted in Sutro's Scientific Publications section after the event.
Sutro Biopharma (Nasdaq: STRO) priced an underwritten offering of 7,868,383 common shares at $13.98 per share, expected to raise approximately $110.0 million in gross proceeds before fees. The offering is expected to close on or about February 11, 2026.
Proceeds, together with existing cash and marketable securities, are intended primarily for general corporate purposes, including funding research, clinical and process development, manufacturing, working capital, and potential acquisitions or investments. Joint bookrunning managers include Leerink Partners, TD Cowen and LifeSci Capital.
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 11:15 AM PT / 2:15 PM ET in San Francisco.
A live webcast will be accessible via the Events & Presentations page of the Investor Relations section at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
Sutro Biopharma (NASDAQ: STRO) regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1).
The Nasdaq Listing Qualifications Department confirmed on Dec 17, 2025 that, as of Dec 16, 2025, Sutro's common stock maintained an average closing price of at least $1.00 following the company's 1:10 reverse stock split that became effective on Dec 3, 2025. As a result, the company's shares are no longer considered below the minimum bid price requirement and the company has regained continued listing compliance.
Sutro Biopharma (NASDAQ: STRO) announced that on December 15, 2025 its Compensation Committee granted 24,500 stock options and 2,000 restricted stock units (RSUs) to new non-executive employees as inducement awards approved under Nasdaq Listing Rule 5635(c)(4).
The awards are governed by the Amended and Restated 2021 Equity Inducement Plan. Vesting for the stock options is 25% at one year then monthly to the fourth anniversary; RSU vesting is 25% at one year then annually to the fourth anniversary, each subject to continued service.
Sutro Biopharma (NASDAQ: STRO) announced dosing of the first cohort in its Phase 1 trial of STRO-004, a tissue factor (TF)–targeting exatecan ADC, on Dec 3, 2025. The open-label, multicenter dose-escalation study will evaluate safety, pharmacokinetics, and preliminary anti-tumor activity in advanced TF-expressing solid tumors including NSCLC, head and neck, cervical, colorectal, pancreatic ductal adenocarcinoma, and bladder cancer.
The program uses Sutro’s cell-free platform to enable site-specific ADCs and supports high entry doses backed by tolerability in non-human primates up to 50 mg/kg. Initial clinical data are expected in mid-2026, and the trial aims to identify a recommended Phase 2 dose rapidly. ClinicalTrials.gov ID: NCT07227168.
Sutro Biopharma (NASDAQ: STRO) announced a 1-for-10 reverse stock split of its common stock effective at 12:01 a.m. ET on December 3, 2025. The split will reduce outstanding shares from approximately 85,193,912 to approximately 8,519,392 and the post-split shares will continue to trade under the symbol STRO with a new CUSIP of 869367201.
The reverse split was previously approved by stockholders on June 6, 2025, and is intended to regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Proportionate adjustments will apply to outstanding equity awards and employee plans; there will be no change to authorized shares or par value.
Sutro Biopharma (NASDAQ: STRO) hosted a virtual R&D Day on Nov 12, 2025 to detail its next‑generation ADC platform and pipeline.
Key updates: STRO‑004, a Tissue Factor ADC, has entered Phase 1 after FDA IND clearance and showed preclinical activity plus a highest non‑severely toxic dose of 50 mg/kg in non‑human primates. Sutro named PTK7 as the target for its first dual‑payload candidate STRO‑227, with an IND submission targeted for 2026/2027. STRO‑006 (ITGB6) showed superior PK versus a Phase 3 comparator and is expected to enter the clinic in 2026. Astellas collaboration and a planned iADC clinical entry are also highlighted. Initial STRO‑004 clinical data are expected mid‑2026.